Relationship between CHA2DS2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation without receiving anticoagulant therapy

Journal of Cardiology

Volumn 59, Issue 3, 2012, Pages 321-328

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Satoh, Yoshihiro ^a   Ozawa, Mahito ^a   Kunugita, Fusanori ^a   Ueda, Hironobu ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic drug; Anticoagulant; Atrial fibrillation; Prognosis; Stroke

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHA2DS2 VASC SCORE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE;

EID: 84860426409     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.01.003     Document Type: Article

References (33)

1. Chugh S.S., Blackshear J.L., Shen W.K., Hammill S.C., Gersh B.J. Epidemiology and natural history of atrial fibrillation. J Am Coll Cardiol 2001, 37:371-378.
2. Ohsawa M., Okayama A., Sakata K., Kato K., Itai K., Onoda T., Ueshima H. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular disease in 1980, 1990 and 2000. J Epidemiol 2005, 15:194-196.
3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987, 147:1561-1564.
4. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
5. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
6. Sopher S.M., Camm A.J. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996, 77:24A-37A.
7. Ogihara T., Kikuchi K., Matsuoka H., Fujita T., Higaki J., Horiuchi M., Imai Y., Imaizumi T., Ito S., Iwao H., Kario K., Kawano Y., Kim-Mitsuyama S., Kimura G., Matsubara H., et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH2009). Hypertens Res 2009, 32:3-107.
8. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias Guidelines for diagnosis and treatment of hyperlipidemia in adults. J Jpn Atheroscler Soc 1997, 25:1-34.
9. Komatsu T., Tachibana H., Sato Y., Ozawa M., Nakamura M., Okumura K. Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007, 71:46-51.
10. Komatsu T., Nakamura S., Suzuki O., Horiuchi D., Yomogida K., Okumura K. Long-term prognosis of the patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004, 68:729-733.
11. Kodama I., Aizawa Y., Inoue H., Ohe T., Ogawa S., Okumura K., Kasanuki H., Katoh T., Kamiya K., Saikawa T., Nakaya H., Nagashima M., Hashimoto K., Hiraoka M., Mitamura H., et al. The guideline for drug treatment of arrhythmia (JCS 2004). Circ J 2004, 68(Suppl. IV):981-1053. (in Japanese).
12. Petersen P., Boysen G., Godtfredsen J. Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989, 1:175-178.
13. Stroke Prevention in Atrial Fibrillation Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994, 343:687-691.
14. Connolly S.J., Laupacis A., Gent M. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991, 18:349-355.
15. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990, 323:1505-1511.
16. Cerebral Embolism Task Force Cardiogenic brain embolism. Arch Neurol 1986, 43:71-84.
17. Stroke Prevention in Atrial Fibrillation Investigators Stroke prevention in atrial fibrillation study. Final results. Circulation 1991, 84:527-539.
18. Tomita F., Kohya T., Sakurai M., Kaji T., Yokoshiki H., Sato M., Sasaki K., Itoh Y., Konno M., Kitabatake A., Hokkaido Atrial Fibrillation Study Group Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20000 cases in Japan. Jpn Circ J 2000, 64:653-658.
19. Sato H., Ishikawa K., Kitabatake A., Ogawa S., Maruyama Y., Yokota Y., Fukuyama T., Doi Y., Mochizuki S., Izumi T., Takekoshi N., Yoshida K., Hiramori K., Origasa H., Uchiyama S., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Trial. Stroke 2006, 37:447-451.
20. Hughes M., Lip G.Y. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008, 99:295-304.
21. Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009, 30:1038-1045.
22. Hart R.G., Pearce L.A., McBride R., Rothbart R.M., Asinger R.W. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999, 30:1223-1229.
23. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010, 137:263-272.
24. Ogawa S., Yamashita T., Yamazaki T., Aizawa Y., Atarashi H., Inoue H., Ohe T., Ohtsu H., Okumura K., Katoh T., Kamakura S., Kumagai K., Kurachi Y., Kodama I., Koretsune Y., et al. Optimal treatment strategy for patients with atrial fibrillation: J-RHYTHM study. Circ J 2009, 73:242-248.
25. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: stroke prevention in atrial fibrillation III study. JAMA 1998, 279:1273-1277.
26. Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999, 131:688-695.
27. 2 Score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. Int Heart J 2010, 51:24-29.
28. Suzuki S., Yamashita T., Ohtsuka T., Sagara K., Uejima T., Oikawa Y., Yajima J., Koike A., Nagashima K., Kirigaya H., Ogasawara K., Sawada H., Aizawa T. Prevalence and prognosis of patients with a atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 2008, 72:914-920.
29. Corley S.D., Epstein A.E., DiMarco J.P., Domanski M.J., Geller N., Greene H.L., Josephson R.A., Kellen J.C., Klein R.C., Krahn A.D., Mickel M., Mitchell L.B., Nelson J.D., Rosenberg Y., Schron E., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004, 109:1509-1513.
30. Komatsu T., Tachibana H., Sato Y., Ozawa M., Kunugida F., Nakamura M. Clinical profiles, efficacy of antiarrhythmic drug therapy and cardiovascular prognosis in patients with first-detected paroxysmal atrial fibrillation. Int Heart J 2011, 52:32-38.
31. Wyse D.G., Waldo A.L., DiMaroco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., Corley S.D., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators, The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigator A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
32. Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., Said S.A., Darmanata J.I., Timmermans A.J., Tijssen J.G., Crijns H.J., Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group A comparison of rate control and rhythm control in patients with recurrent and persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
33. Maehama T., Okura H., Imai K., Saito K., Yamada R., Koyama T., Hayashida A., Neishi Y., Kawamoto T., Yoshida K. Systemic inflammation and left atrial thrombus in patients with non-rheumatic atrial fibrillation. J Cardiol 2010, 56:118-124.